Clinical Relevance of CHEK2 And NBN Mutations in the Macedonian Population

1. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008; 40(1): 17-22.10.1038/ng.2007.53Search in Google Scholar

2. Nevanlinna H, Bartek J. The CHEK2 gene and inherited breast cancer susceptibility. Oncogene. 2006; 25(43): 5912-5919.10.1038/sj.onc.1209877Search in Google Scholar

3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999; 286(5449): 2528-2531.10.1126/science.286.5449.2528Search in Google Scholar

4. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002; 71(2): 432-438.10.1086/341943Search in Google Scholar

5. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, et al. Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat. 2004; 83(1): 91-93.10.1023/B:BREA.0000010697.49896.03Search in Google Scholar

6. Cybulski C, Huzarski T, Gorski B, Masojc B, Mier- zejewski M, Debniak T, et al. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res. 2004; 64(8): 2677-2679.10.1158/0008-5472.CAN-04-0341Search in Google Scholar

7. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, et al. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer. 2005; 116(2): 263-266.10.1002/ijc.21022Search in Google Scholar

8. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A, et al. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer. 2004; 110(3): 320-325.10.1002/ijc.20073Search in Google Scholar

9. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12): 1379-1388.10.1001/jama.295.12.1379Search in Google Scholar

10. Cybulski C, Wokołorczyk D, Huzarski T, Byrski T, Gronwald J, Górski B, et al. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat. 2007; 102(1): 119-122.10.1007/s10549-006-9320-ySearch in Google Scholar

11. Liu C, Wang Y, Wang QS, Wang YJ. The CHEK2 I157T variant and breast cancer susceptibility: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012; 13(4): 1355-1360.10.7314/APJCP.2012.13.4.1355Search in Google Scholar

12. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, Saar K, et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell. 1998; 93(3): 467-476.10.1016/S0092-8674(00)81174-5Search in Google Scholar

13. Varon R, Seemanova E, Chrzanowska K, Hnateyko O, Piekutowska-Abramczuk D, Krajewska- Walasek M, et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations. Eur J Hum Genet. 2000; 8(11): 900-902.10.1038/sj.ejhg.5200554Search in Google Scholar

14. Bogdanova N, Feshchenko S, Schurmann P, Waltes R, Wieland B, Hillemanns P, et al. Nijmegen breakage syndrome mutations and risk of breast cancer. Int J Cancer. 2008; 122(4): 802-806.10.1002/ijc.23168Search in Google Scholar

15. Maleva I, Madjunkova S, Bozhinovski G, Smickova E, Kondov G, Spiroski Z, et al. Genetic variation of the brca1 and brca2 genes in Macedonian patients. Balkan J Med Genet. 2012; 15(Suppl): 81-85.10.2478/v10034-012-0025-8Search in Google Scholar

16. de Jong MM, van der Graaf WTA, Nolte IM, Te Meerman GJ, Oosterwijk JC, van der Steege G, et al. Increased CHEK2 1100delC genotype frequency (also) in unselected breast cancer patients (conference abstract). American Society of Clinical Oncology Annual Meeting Proceedings (Post- Meeting Edition), New Orleans, LA, USA, June 5-8 2004. J Clin Oncol. 2004; 22(14S): 9536.10.1200/jco.2004.22.90140.9536Search in Google Scholar

17. Einarsdottir K, Humphreys K, Bonnard C, Palmgren J, Iles MM, Sjolander A, et al. Linkage disequilibrium mapping of CHEK2: Common variation and breast cancer risk. PLoS Med. 2006; 3(6): e168. doi: 10.1371/ journal. pmed.0030168.10.1371/journal.pmed.0030168Search in Google Scholar

18. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol. 2007; 25(1): 57-63.10.1200/JCO.2005.05.5160Search in Google Scholar

19. Mateus Pereira LH, Sigurdson AJ, Doody MM, Pineda MA, Alexander BH, Greene MH, et al. CHEK2: 1100delC and female breast cancer in the United States. Int J Cancer. 2004; 112(3): 541-543.10.1002/ijc.20439Search in Google Scholar

20. Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, et al. German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer. 2005; 41(18): 2896-2903.10.1016/j.ejca.2005.04.049Search in Google Scholar

21. Kleibl Z, Novotny J, Bezdickova D, Malik R, Klei-blova P, Foretova L, et al. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. Breast Cancer Res Treat. 2005; 90(2): 165-167. 10.1007/s10549-004-4023-8Search in Google Scholar